North America Clinical Diagnostics Market: Size, Growth, and Opportunities

The North America clinical diagnostics market is a cornerstone of modern healthcare, enabling timely detection, diagnosis, and monitoring of diseases. Valued at USD 84.18 billion in 2024, the market is projected to reach USD 89.63 billion in 2025 and further expand to USD 148.12 billion by 2033, registering a CAGR of 6.48% during the forecast period. This growth is fueled by increasing healthcare needs, technological advancements, and the rising prevalence of chronic and infectious diseases across the United States and Canada.

📥 Download Sample

Market Drivers in North America

One of the primary growth drivers is the rising incidence of chronic diseases and infections. In 2023 alone, the American Cancer Society reported 1.9 million new cancer cases in the U.S., reinforcing the urgent demand for effective diagnostic solutions. Similarly, the American Clinical Laboratory Association highlighted that over 7 billion clinical lab tests are conducted annually in the country, demonstrating the indispensable role diagnostics play in healthcare.

Another key factor is the shift toward point-of-care testing (POCT). Portable diagnostic tools and at-home test kits are gaining popularity due to their convenience and rapid results. For instance, BioGX introduced its CE-marked three-gene multiplex POC COVID-19 test in 2022, which received FDA emergency clearance, exemplifying the market’s pivot toward decentralized diagnostics.

Automation and AI integration are also reshaping the sector. Partnerships such as the 2022 collaboration between Premas Life Sciences and Beckman Coulter highlight the region’s focus on advanced liquid handling technologies and enhanced lab efficiency. These innovations not only reduce human error but also improve turnaround times, directly impacting patient care.

United States Market Highlights

The U.S. clinical diagnostics sector dominates the regional market due to its advanced healthcare infrastructure, supportive policies, and strong industry presence. Consolidation activities further underscore its competitive edge. For example, in March 2024, Labcorp acquired select assets from BioReference Health’s diagnostics business to expand its test portfolio and strengthen market positioning. Such moves highlight ongoing investment and growth opportunities in the U.S. diagnostics space.

Canada Market Highlights

Canada is actively investing in diagnostic innovation to address growing healthcare needs. In November 2022, the Canadian government committed USD 2 million to SQI Diagnostics Inc., supporting rapid testing capabilities for respiratory conditions like their RALI-fast test. These investments not only boost diagnostic accuracy but also expand manufacturing capacity and create jobs, signaling a promising growth trajectory for the Canadian market.

Key Players in North America Clinical Diagnostics Market

North America hosts several leading players shaping the competitive landscape through innovation and partnerships:

• Abbott Laboratories
• Hoffmann-La Roche AG
• Danaher Corporation
• Bio-Rad Laboratories Inc.
• Becton, Dickinson and Company
• Qiagen NV
• Sonic Healthcare Ltd.
• NeoGenomics, Inc.

For example, in July 2024, NeoGenomics announced the launch of two next-generation sequencing assays—Neo AMLExpress for acute myeloid leukemia and Neo PanTracer LBx for pan-cancer genomic profiling. These innovations reflect the company’s focus on precision oncology and highlight the region’s leadership in advanced cancer diagnostics.

Opportunities and Outlook

The future of clinical diagnostics in North America looks promising, driven by the rise of personalized medicine, gene therapy monitoring, and liquid biopsy technologies. For instance, researchers at Stanford University developed a liquid biopsy test in 2023 to monitor CAR-T cell therapy, showcasing how advanced diagnostics can guide treatment decisions in real time.

Affordability challenges for high-end molecular diagnostics remain, particularly in underserved regions, but opportunities abound in regenerative medicine and AI-driven testing solutions. Companies that prioritize innovation, strategic collaborations, and market expansion are well-positioned to capitalize on this momentum.

Conclusion

North America’s clinical diagnostics market continues to thrive as innovation and demand converge. With a projected market size of USD 148.12 billion by 2033, the region is set to remain at the forefront of global healthcare advancements. Key players, supportive government initiatives, and evolving patient needs are shaping a dynamic and competitive landscape that offers robust growth opportunities for investors and healthcare stakeholders.

About Us:

Straits Research is a global market intelligence firm delivering actionable insights across industries. We provide in-depth market reports, competitive analysis, and strategic recommendations to help businesses make informed decisions.

Contact Us:

For inquiries, partnerships, or customized research solutions, please reach out via our Contact Page.